Your session is about to expire
← Back to Search
Naloxegol and Opioid-induced Constipation
Phase 2 & 3
Waitlist Available
Led By Scott McCardle, MD
Research Sponsored by TriHealth Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-operative day 5
Summary
This trial is testing whether adding naloxegol to a cardiac surgery pre-operative regimen is effective.
Eligible Conditions
- Constipation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ post-operative day 5
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-operative day 5
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Time to substantial bowel movement
Secondary study objectives
Rescue medications
Other study objectives
Length of stay
Side effects data
From 2022 Phase 4 trial • 136 Patients • NCT032357391%
Troponin elevation and ST elevation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment-Naloxegol
Placebo Arm
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: NaloxegolExperimental Treatment1 Intervention
naloxegol 25 mg pill
Group II: PlaceboPlacebo Group1 Intervention
placebo pill
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Naloxegol 25 MG
2017
Completed Phase 4
~140
Find a Location
Who is running the clinical trial?
TriHealth Inc.Lead Sponsor
99 Previous Clinical Trials
53,543 Total Patients Enrolled
2 Trials studying Constipation
169 Patients Enrolled for Constipation
Scott McCardle, MDPrincipal InvestigatorBethesda North TriHealth Hospital